Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Abbott approval narrows competitive gap to DexCom, says Piper Sandler » 09:10
06/15/20
06/15
09:10
06/15/20
09:10
DXCM

DexCom

$370.29 /

+7.69 (+2.12%)

, ABT

Abbott

$89.01 /

+1.19 (+1.36%)

, TNDM

TNDM

/

+

, PODD

Insulet

$180.48 /

-0.485 (-0.27%)

The FDA this morning…

The FDA this morning announced the 510K approval of Abbott's (ABT) Freestyle Libre 2.0 with the integrated continuous glucose monitoring designation. The device has Bluetooth technology and provides patients with real-time alerts on both the hypo and hyper side, Piper Sandler analyst Matt O'Brien tells investors in a research note. However, the alarm functionality is not as robust as DexCom's (DXCM) offering as the alarms do not appear to have predictive features, adds O'Brien. The analyst, however, believes Abbott has narrowed the competitive gap to DexCom. It will take time for Abbott to work with Tandem Diabetes (TNDM) and Insulet (PODD) to fully integrate the iCGM sensor into the respective AID systems, says O'Brien. He still remains positive on DexCom's competitive positioning given the more accurate sensor and current ability to integrate with AID systems. DexCom in premarket trading is down 1% to $365.50.

ShowHide Related Items >><<
TNDM TNDM
/

+

PODD Insulet
$180.48 /

-0.485 (-0.27%)

DXCM DexCom
$370.29 /

+7.69 (+2.12%)

ABT Abbott
$89.01 /

+1.19 (+1.36%)

DXCM DexCom
$370.29 /

+7.69 (+2.12%)

06/10/20 Piper Sandler
Tandem Diabetes the 'standout' in Piper endocrinologist survey
06/09/20 Cowen
DexCom price target raised to $430 from $360 at Cowen
06/03/20 Citi
DexCom price target raised to $440 from $361 at Citi
05/27/20 Piper Sandler
DexCom price target raised to $450 from $375 at Piper Sandler
ABT Abbott
$89.01 /

+1.19 (+1.36%)

06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
06/01/20
Fly Intel: Top five analyst downgrades
05/31/20 Goldman Sachs
Abbott downgraded to Sell from Neutral at Goldman Sachs
TNDM TNDM
/

+

06/03/20 Citi
Tandem Diabetes price target raised to $94 from $81 at Citi
04/27/20 Guggenheim
Guggenheim ups DexCom target, concerned about Tandem Diabetes
04/24/20 SVB Leerink
Tandem Diabetes downgraded to Market Perform from Outperform at SVB Leerink
PODD Insulet
$180.48 /

-0.485 (-0.27%)

06/05/20 Piper Sandler
Insulet offered positive comment on data, says Piper Sandler
05/08/20 Baird
Insulet price target raised to $242 from $189 at Baird
05/08/20 SVB Leerink
Insulet price target raised to $230 from $200 at SVB Leerink
TNDM TNDM
/

+

PODD Insulet
$180.48 /

-0.485 (-0.27%)

DXCM DexCom
$370.29 /

+7.69 (+2.12%)

ABT Abbott
$89.01 /

+1.19 (+1.36%)

DXCM DexCom
$370.29 /

+7.69 (+2.12%)

ABT Abbott
$89.01 /

+1.19 (+1.36%)

TNDM TNDM
/

+

PODD Insulet
$180.48 /

-0.485 (-0.27%)

DXCM DexCom
$370.29 /

+7.69 (+2.12%)

ABT Abbott
$89.01 /

+1.19 (+1.36%)

TNDM TNDM
/

+

ABT Abbott
$89.01 /

+1.19 (+1.36%)

Recommendations
Tandem Diabetes the 'standout' in Piper endocrinologist survey » 05:01
06/10/20
06/10
05:01
06/10/20
05:01
TNDM

TNDM

/

+

, DXCM

DexCom

$380.00 /

+11.21 (+3.04%)

, PODD

Insulet

$181.98 /

+1.255 (+0.69%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien surveyed 30 endocrinologists, who collectively treat over 26,000 diabetic patients annually, on current and future technologies in the diabetes space. Overall, the responses indicated that use of continuous glucose monitoring and insulin pumps is likely to continue to "march higher at a robust clip," with uptake in the type-2 market in-line to better than modeled for both pumps and monitors, O'Brien tells investors in a research note. Tandem Diabetes (TNDM) was the "standout" from the survey, followed by DexCom (DXCM), with Insulet (PODD) a "bit of laggard" in the out-years, adds the analyst. O'Brien says the survey pointed to "solid" new patient growth for the diabetes pure-plays in 2020 despite COVID-19.

ShowHide Related Items >><<
TNDM TNDM
/

+

PODD Insulet
$181.98 /

+1.255 (+0.69%)

DXCM DexCom
$380.00 /

+11.21 (+3.04%)

TNDM TNDM
/

+

06/03/20 Citi
Tandem Diabetes price target raised to $94 from $81 at Citi
04/27/20 Guggenheim
Guggenheim ups DexCom target, concerned about Tandem Diabetes
04/24/20 SVB Leerink
Tandem Diabetes downgraded to Market Perform from Outperform at SVB Leerink
04/24/20 SVB Leerink
Tandem Diabetes downgraded to Market Perform from Outperform at SVB Leerink
DXCM DexCom
$380.00 /

+11.21 (+3.04%)

06/09/20 Cowen
DexCom price target raised to $430 from $360 at Cowen
06/03/20 Citi
DexCom price target raised to $440 from $361 at Citi
05/27/20 Piper Sandler
DexCom price target raised to $450 from $375 at Piper Sandler
05/14/20 Wells Fargo
DexCom initiated with an Equal Weight at Wells Fargo
PODD Insulet
$181.98 /

+1.255 (+0.69%)

06/05/20 Piper Sandler
Insulet offered positive comment on data, says Piper Sandler
05/08/20 Baird
Insulet price target raised to $242 from $189 at Baird
05/08/20 SVB Leerink
Insulet price target raised to $230 from $200 at SVB Leerink
05/08/20 Citi
Insulet price target raised to $250 from $206 at Citi
TNDM TNDM
/

+

PODD Insulet
$181.98 /

+1.255 (+0.69%)

DXCM DexCom
$380.00 /

+11.21 (+3.04%)

DXCM DexCom
$380.00 /

+11.21 (+3.04%)

TNDM TNDM
/

+

PODD Insulet
$181.98 /

+1.255 (+0.69%)

DXCM DexCom
$380.00 /

+11.21 (+3.04%)

TNDM TNDM
/

+

Recommendations
DexCom price target raised to $430 from $360 at Cowen » 07:29
06/09/20
06/09
07:29
06/09/20
07:29
DXCM

DexCom

$368.79 /

+4.06 (+1.11%)

Cowen analyst Ryan…

Cowen analyst Ryan Blicker raised the firm's price target on DexCom to $430 from $360 and keeps an Outperform rating on the shares. The analyst thinks its larger TAM is coming into view over the next 12-24 months, that causes him to raise his estimates, and increases the visibility and confidence that double digit revenue growth can be maintained for the next 10 years.

ShowHide Related Items >><<
DXCM DexCom
$368.79 /

+4.06 (+1.11%)

DXCM DexCom
$368.79 /

+4.06 (+1.11%)

06/03/20 Citi
DexCom price target raised to $440 from $361 at Citi
05/27/20 Piper Sandler
DexCom price target raised to $450 from $375 at Piper Sandler
05/14/20 Wells Fargo
DexCom initiated with an Equal Weight at Wells Fargo
04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
DXCM DexCom
$368.79 /

+4.06 (+1.11%)

DXCM DexCom
$368.79 /

+4.06 (+1.11%)

DXCM DexCom
$368.79 /

+4.06 (+1.11%)

Recommendations
DexCom price target raised to $440 from $361 at Citi » 07:34
06/03/20
06/03
07:34
06/03/20
07:34
DXCM

DexCom

$375.09 /

-3.65 (-0.96%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch raised the firm's price target on DexCom to $440 from $361 and reiterates a Buy rating on the shares. A survey of 30 physicians demonstrates that while new patient additions are likely to slow during COVID-19, demand for new technology in diabetes is significant, including Tandem's Control IQ and Dexcom's G6, Wuensch tells investors in a research note. Diabetes stocks are up almost 40% year-to-date on average, but there is "more to come in this MedTech segment, underscored by clinical data," says the analyst.

ShowHide Related Items >><<
DXCM DexCom
$375.09 /

-3.65 (-0.96%)

DXCM DexCom
$375.09 /

-3.65 (-0.96%)

05/27/20 Piper Sandler
DexCom price target raised to $450 from $375 at Piper Sandler
05/14/20 Wells Fargo
DexCom initiated with an Equal Weight at Wells Fargo
04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
DXCM DexCom
$375.09 /

-3.65 (-0.96%)

DXCM DexCom
$375.09 /

-3.65 (-0.96%)

DXCM DexCom
$375.09 /

-3.65 (-0.96%)

Over a month ago
Recommendations
DexCom price target raised to $450 from $375 at Piper Sandler » 05:14
05/27/20
05/27
05:14
05/27/20
05:14
DXCM

DexCom

$381.60 /

-23.55 (-5.81%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on DexCom to $450 from $375 and keeps an Overweight rating on the shares. The current premium for DexCom implies that the company successfully enters the non-intensive, inpatient, and gestational markets, O'Brien tells investors in a research note. However, there is "plenty of upside" remaining and DexCom is "building the necessary foundation for sustainable top-line growth over the next several years," adds the analyst. "While the price of admission is not cheap, we think DexCom is a must own Med Tech name," says O'Brien.

ShowHide Related Items >><<
DXCM DexCom
$381.60 /

-23.55 (-5.81%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

05/14/20 Wells Fargo
DexCom initiated with an Equal Weight at Wells Fargo
04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
DXCM DexCom
$381.60 /

-23.55 (-5.81%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

General News
White House statement on President's action to protect seniors with diabetes » 17:33
05/26/20
05/26
17:33
05/26/20
17:33
DXCM

DexCom

$381.60 /

-23.55 (-5.81%)

, TNDM

TNDM

/

+

, MDT

Medtronic

$97.15 /

+2.44 (+2.58%)

, NVO

Novo Nordisk

$63.36 /

-1.5 (-2.31%)

, JNJ

Johnson & Johnson

$144.48 /

+0.11 (+0.08%)

, LLY

Eli Lilly

$147.88 /

-3.27 (-2.16%)

, SNY

Sanofi

$47.26 /

-0.05 (-0.11%)

The White House said, in…

The White House said, in part, on the press call, on the President's action to protect seniors with diabetes: "To give you a sense of the scope of what that means: Roughly one in three Medicare beneficiaries has diabetes, and millions use one or more of the common forms of insulin. Seniors who sign up for these new plans will have no more than a 35-dollar co-pay for a month's supply of all types of insulin. That results in approximately a 66 percent, or two-thirds, reduction in out-of-pocket costs. The result: For the third year in a row, the average basic premium for Medicare Part D prescription drug prices has declined, saving beneficiaries $1.9 billion in premiums over time. Three years into the Trump administration, third consecutive year that these Medicare Part D premiums have declined. That's called causation, not coincidence. We continue to deliver creative solutions that result in historic agreements." Companies that may be impacted by this announcement include DexCom (DXCM), Tandem Diabetes (TNDM), Medtronic (MDT) Novo Nordisk (NVO), Johnson & Johnson (JNJ), Eli Lilly (LLY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
TNDM TNDM
/

+

SNY Sanofi
$47.26 /

-0.05 (-0.11%)

NVO Novo Nordisk
$63.36 /

-1.5 (-2.31%)

MDT Medtronic
$97.15 /

+2.44 (+2.58%)

LLY Eli Lilly
$147.88 /

-3.27 (-2.16%)

JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

05/14/20 Wells Fargo
DexCom initiated with an Equal Weight at Wells Fargo
04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
TNDM TNDM
/

+

04/27/20 Guggenheim
Guggenheim ups DexCom target, concerned about Tandem Diabetes
04/24/20 SVB Leerink
Tandem Diabetes downgraded to Market Perform from Outperform at SVB Leerink
04/24/20 SVB Leerink
Tandem Diabetes downgraded to Market Perform from Outperform at SVB Leerink
04/20/20 Craig-Hallum
Tandem Diabetes price target lowered to $102 from $108 at Craig-Hallum
MDT Medtronic
$97.15 /

+2.44 (+2.58%)

05/26/20 SunTrust
Medtronic price target lowered to $105 from $130 at SunTrust
05/21/20 Piper Sandler
Medtronic price target lowered to $120 from $135 at Piper Sandler
05/21/20 Piper Sandler
Medtronic robot delay positive for Intuitive Surgical, says Piper Sandler
05/14/20 DZ Bank
Medtronic downgraded to Hold from Buy at DZ Bank
NVO Novo Nordisk
$63.36 /

-1.5 (-2.31%)

05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 UBS
Novo Nordisk downgraded to Neutral from Buy at UBS
JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
04/28/20 UBS
Johnson & Johnson downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$147.88 /

-3.27 (-2.16%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
SNY Sanofi
$47.26 /

-0.05 (-0.11%)

05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
05/26/20 Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
05/26/20 SVB Leerink
Sanofi overhang removed, Regeneron capital structure improving, says SVB Leerink
TNDM TNDM
/

+

SNY Sanofi
$47.26 /

-0.05 (-0.11%)

NVO Novo Nordisk
$63.36 /

-1.5 (-2.31%)

MDT Medtronic
$97.15 /

+2.44 (+2.58%)

LLY Eli Lilly
$147.88 /

-3.27 (-2.16%)

JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

SNY Sanofi
$47.26 /

-0.05 (-0.11%)

NVO Novo Nordisk
$63.36 /

-1.5 (-2.31%)

MDT Medtronic
$97.15 /

+2.44 (+2.58%)

LLY Eli Lilly
$147.88 /

-3.27 (-2.16%)

JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

TNDM TNDM
/

+

SNY Sanofi
$47.26 /

-0.05 (-0.11%)

NVO Novo Nordisk
$63.36 /

-1.5 (-2.31%)

MDT Medtronic
$97.15 /

+2.44 (+2.58%)

LLY Eli Lilly
$147.88 /

-3.27 (-2.16%)

JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

DXCM DexCom
$381.60 /

-23.55 (-5.81%)

TNDM TNDM
/

+

SNY Sanofi
$47.26 /

-0.05 (-0.11%)

MDT Medtronic
$97.15 /

+2.44 (+2.58%)

JNJ Johnson & Johnson
$144.48 /

+0.11 (+0.08%)

Initiation
DexCom initiated with an Equal Weight at Wells Fargo » 06:26
05/14/20
05/14
06:26
05/14/20
06:26
DXCM

DexCom

$407.07 /

-4.34 (-1.05%)

Wells Fargo analyst Larry…

Wells Fargo analyst Larry Biegelsen initiated coverage of DexCom with an Equal Weight rating and $420 price target. While DexCom's core continuous glucose monitoring market will be one of the fastest growing major MedTech markets over the next five years and consensus estimates offer upside potential, the current valuation reflects some of the potential sources of upside, Biegelsen tells investors in a research note.

ShowHide Related Items >><<
DXCM DexCom
$407.07 /

-4.34 (-1.05%)

DXCM DexCom
$407.07 /

-4.34 (-1.05%)

04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
04/29/20 SVB Leerink
DexCom price target raised to $400 from $385 at SVB Leerink
DXCM DexCom
$407.07 /

-4.34 (-1.05%)

DXCM DexCom
$407.07 /

-4.34 (-1.05%)

DXCM DexCom
$407.07 /

-4.34 (-1.05%)

Hot Stocks
DexCom to replace Allergan in S&P 500 at open on 5/12 » 04:55
05/12/20
05/12
04:55
05/12/20
04:55
DXCM

DexCom

$421.61 /

+16.34 (+4.03%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

AbbVie (ABBV) is…

AbbVie (ABBV) is acquiring Allergan (AGN) in a transaction expected to be completed soon pending final conditions.

ShowHide Related Items >><<
DXCM DexCom
$421.61 /

+16.34 (+4.03%)

AGN Bought by ABBV
$193.08 /

+ (+0.00%)

DXCM DexCom
$421.61 /

+16.34 (+4.03%)

04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
04/29/20 SVB Leerink
DexCom price target raised to $400 from $385 at SVB Leerink
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

05/01/20 Piper Sandler
Piper Sandler remains a buyer of 'resilient' AbbVie after earnings
04/21/20 SunTrust
Allergan downgraded to Hold from Buy at SunTrust
04/21/20 SunTrust
Allergan downgraded to Hold from Buy at SunTrust
04/20/20 RBC Capital
AbbVie upgraded to Outperform from Sector Perform at RBC Capital
DXCM DexCom
$421.61 /

+16.34 (+4.03%)

AGN Bought by ABBV
$193.08 /

+ (+0.00%)

DXCM DexCom
$421.61 /

+16.34 (+4.03%)

AGN Bought by ABBV
$193.08 /

+ (+0.00%)

DXCM DexCom
$421.61 /

+16.34 (+4.03%)

AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGN Bought by ABBV
$193.08 /

+ (+0.00%)

Syndicate
DexCom announces $850M of convertible senior notes due 2025  07:11
05/11/20
05/11
07:11
05/11/20
07:11
DXCM

DexCom

$405.27 /

+0.94 (+0.23%)

 
ShowHide Related Items >><<
DXCM DexCom
$405.27 /

+0.94 (+0.23%)

04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
04/29/20 SVB Leerink
DexCom price target raised to $400 from $385 at SVB Leerink
Conference/Events
DexCom participates in a conference call hosted by Morgan Stanley » 09:25
05/08/20
05/08
09:25
05/08/20
09:25
DXCM

DexCom

$404.33 /

+38.49 (+10.52%)

Medical Technology…

Medical Technology Analyst Lewis holds a conference call with Chairman & CEO Sayer on May 8 at 10 am hosted by Morgan Stanley.

ShowHide Related Items >><<
DXCM DexCom
$404.33 /

+38.49 (+10.52%)

04/29/20 Stifel
DexCom price target raised to $385 from $270 at Stifel
04/29/20 Oppenheimer
DexCom price target raised to $360 from $305 at Oppenheimer
04/29/20 Cowen
DexCom price target raised to $360 from $300 at Cowen
04/29/20 SVB Leerink
DexCom price target raised to $400 from $385 at SVB Leerink

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.